<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456924</url>
  </required_header>
  <id_info>
    <org_study_id>2914-002</org_study_id>
    <nct_id>NCT00456924</nct_id>
  </id_info>
  <brief_title>Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914</brief_title>
  <official_title>Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate continuous administration of low doses of
      VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid
      hormone parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovarian hormones</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>follicular development</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>endometrial histology</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>menstural bleeding patterns</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cervical mucus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VA2914 concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory parameters</measure>
  </secondary_outcome>
  <enrollment>48</enrollment>
  <condition>Contraception</condition>
  <condition>Gynecologic Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VA2914</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women in good general health with regular, ovulatory menstrual cycles

          -  age 18-35

          -  not pregnant

          -  not sexually active or reliably use barrier methods of contraception

          -  normal liver and renal functions and normal laboratory exams

        Exclusion Criteria:

          -  pregnant or breastfeeding

          -  oral contraception, IUD or other hormonal treatment

          -  use of agents known to induce hepatic P450

          -  cardiovascular disorder

          -  hepatic, renal, or gastrointestinal disorder

          -  metrorrhagia

          -  abnormal transvaginal ultrasound (at baseline)

          -  history of abnormal endometrial biopsy,

          -  cancer

          -  depression

          -  mental illness

          -  epilepsy

          -  migraines

          -  abnormal Pap Smear requiring further exploratory examination

          -  anovulatory cycle before treatment

          -  extreme overweight or underweight (body mass index &lt; 16 ou &gt;28)

          -  subjects unlikely to comply with the protocol, e.g., uncooperative attitude, inability
             to return for follow-up visits, and unlikelihood of completing the study

          -  use of narcotics

          -  more than 10 cigarettes per day, more than 2 glasses of wine/beer per day

          -  surgical procedures planned in the 6 months following screening visit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Bouchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Antoine Hospital, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liege University Hospital</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Rosalie Clinique</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoine Beclere Hospital</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007 Sep;92(9):3582-9. Epub 2007 Jun 19.</citation>
    <PMID>17579200</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>June 16, 2010</last_update_submitted>
  <last_update_submitted_qc>June 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2010</last_update_posted>
  <keyword>progesterone receptor modulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

